Human Aldose Reductase (AKR1B1) Enzyme
234€ (10 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Human Aldose Reductase (AKR1B1) Enzyme
category
Proteins and Peptides
provider
Abbexa
reference
abx073056
tested applications
SDS-PAGE
Description
Aldose Reductase is a recombinant enzyme.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Proteins and Peptides |
| Immunogen Target | Aldose Reductase (AKR1B1) |
| Host | E. coli |
| Recommended Dilution | Optimal dilutions/concentrations should be determined by the end user. |
| Origin | Human |
| Expression | Recombinant |
| Purity | > 95% (SDS-PAGE) |
| Size 1 | 10 µg |
| Size 2 | 50 µg |
| Size 3 | 1 mg |
| Form | Liquid |
| Tested Applications | SDS-PAGE |
| Availability | Shipped within 5-10 working days. |
| Storage | Store at 4 °C if the entire vial will be used within 2-4 weeks. Store at -20 °C for long term storage. For long term storage, it is recommended to add a carrier protein (0.1% HSA or BSA). Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | P15121 |
| Gene ID | 231 |
| NCBI Accession | NP_001619.1 |
| OMIM | 103880 |
| Alias | AKR1B1,ADR ALDR1,ALR2,AR |
| Background | Protein AKR1B1 |
| Status | RUO |
| Note | This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use. |
Descripción
AKR1B1, also known as aldose reductase, is a key enzyme in the polyol pathway that converts glucose to sorbitol under hyperglycemic conditions. It has a significant role in the pathogenesis of diabetic complications, such as neuropathy, nephropathy, and retinopathy, as sorbitol accumulation induces osmotic stress and oxidative damage. AKR1B1 also metabolizes reactive aldehydes, including lipid peroxidation products like 4-hydroxynonenal (4-HNE), contributing to cellular detoxification under oxidative stress. Its overactivation under diabetic and inflammatory conditions exacerbates oxidative stress and inflammatory signaling pathways. AKR1B1 inhibitors have been developed as potential therapeutic agents for managing diabetic complications. Beyond diabetes, AKR1B1 is involved in steroid metabolism and the detoxification of xenobiotics. It has also been implicated in cancer progression, as its expression is upregulated in some tumors, promoting proliferation and chemoresistance by reducing reactive aldehydes and maintaining cellular redox balance.
Related Products
Human AKR1B1 (Aldose reductase) ELISA Kit
Ver Producto
Rat AKR1B1 (Aldose reductase) ELISA Kit
Ver Producto
AKR1B1 antibody
This gene encodes a member of the aldo/keto reductase superfamily, which consists of more than 40 known enzymes and proteins. This member catalyzes the reduction of a number of aldehydes, including the aldehyde form of glucose, and is thereby implicated in the development of diabetic complications by catalyzing the reduction of glucose to sorbitol. Multiple pseudogenes have been identified for this gene. The nomenclature system used by the HUGO Gene Nomenclature Committee to define human aldo-keto reductase family members is known to differ from that used by the Mouse Genome Informatics database.
Ver Producto